Aberdeen Group
DYN icon

Aberdeen Group’s Dyne Therapeutics DYN Stock Holding History

Aberdeen Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9M Buy
1,430,384
+322,239
+29% +$5.56M 0.04% 342
2025
Q4 		$21.7M Buy
1,108,145
+551,412
+99% +$10.4M 0.03% 399
2025
Q3 		$7.04M Buy
556,733
+72,770
+15% +$830K 0.01% 662
2025
Q2 		$4.61M Buy
483,963
+169,377
+54% +$1.86M 0.01% 712
2025
Q1 		$3.29M Buy
314,586
+288,783
+1,119% +$4.13M 0.01% 717
2024
Q4 		$608K Buy
+25,803
New +$763K ﹤0.01% 861
2024
Q3 		– Sell
-17,869
Closed -$631K – 930
2024
Q2 		$631K Buy
+17,869
New +$519K ﹤0.01% 847

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Aberdeen Group's DYN Position: Q1 2026 in Review

Aberdeen Group increased its Dyne Therapeutics (DYN) stake by 29% in Q1 2026, buying an estimated $5.56M and bringing the position to 1,430,384 shares worth $25.9M. The position accounts for 0.04% of the portfolio, ranked #342.

Aberdeen Group first reported a position in DYN in Q2 2024 and has held it in 7 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Aberdeen Group held 1,430,384 shares of Dyne Therapeutics worth $25.9M as of Q1 2026.
  • Aberdeen Group bought 322,239 Dyne Therapeutics shares in Q1 2026, an estimated $5.56M.
  • Dyne Therapeutics made up 0.04% of Aberdeen Group's portfolio in Q1 2026, its #342 holding.
  • Aberdeen Group first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.